«上一篇/Previous Article|本期目录/Table of Contents|下一篇/Next Article»

《内科》[ISSN:1006-6977/CN:61-1281/TN]

卷:

15卷

期数:

2020年06

页码:

650-653

栏目:

论著

出版日期:

2020-12-31

文章信息/Info

Title:

Clinical effect of Ningxin Huoxue Qutan decoction in the adjuvant treatment of angina pectoris after PCI in patients with acute coronary syndrome and its effects on serum vWF and CD62p levels

文章编号:

1673-7768（2020）06-0650-04

作者:

常孟洁1; 张丽霞2; 袁清茹1; 张国芳1; 高颖1

1 郑州市第九人民医院心内科，河南省郑州市450000；2 郑州市惠济区人民医院普内科，河南省郑州市450000

Author(s):

CHANG Mengjie1;  ZHANG Lixia2;  YUAN Qingru1;  ZHANG Guofang1;  Gao Ying1

1 Department of Cardiology, Zhengzhou Ninth People′s Hospital, Zhengzhou 450000, Henan Province, China; 2 Department of General Internal Medicine, Huiji District People′s Hospital of Zhengzhou, Zhengzhou 450000, Henan Province, China

关键词:

急性冠脉综合征; 心绞痛; 宁心活血祛痰汤; 经皮冠状动脉介入术; P选择素; 血管性血友病因子

Keywords:

Acute coronary syndrome;  Angina pectoris;  Ningxin Huoxue Qutan decoction;  Percutaneous coronary intervention;  P-selectin;  Von Willebrand factor

分类号:

R 543.3

DOI:

DOI：10.16121/j.cnki.cn45-1347/r.2020.06.05

文献标志码:

A

摘要:

目的探讨宁心活血祛痰汤辅助治疗急性冠脉综合征（ACS）患者经皮冠状动脉介入术（PCI）术后心绞痛的临床效果及对患者血清血管性血友病因子（vWF）、P选择素（CD62p）水平的影响。方法选择2018年2月至2020年2月在我院治疗的ACS患者84例，采用随机数字表法分为两组，每组42例。对照组患者给予PCI术及常规治疗，实验组患者在此基础上，加用宁心活血祛痰汤辅助治疗，疗程2个月。比较两组患者的临床疗效；比较两组患者治疗前后的vWF、CD62p、糖蛋白(GP)Ⅱb/Ⅲa受体复合物水平。结果实验组患者的治疗总有效率（90.48%）显著高于对照组（71.43%），差异有统计学意义（P＜0.05）。治疗前，两组患者的血清vWF、P选择素CD62p、GP Ⅱb/Ⅲa受体复合物水平比较，差异无统计学意义（P＞0.05）；治疗2个月后，实验组患者的血清CD62p、vWF、GPⅡb/Ⅲa受体复合物水平显著低于对照组，差异有统计学意义（P＜0.05）。治疗过程中，两组患者的肝肾功能、尿常规、血常规无明显异常，无明显不良反应发生。结论宁心活血祛痰汤辅助治疗能有效改善ACS患者PCI术后的心绞痛病情，改善患者血管内皮细胞功能和血小板活性，治疗安全性高。

Abstract:

ObjectiveTo explore the clinical effect of Ningxin Huoxue Qutan decoction in the adjuvant treatment of angina pectoris after percutaneous coronary intervention (PCI) in patients with acute coronary syndrome (ACS), and its effects on serum von Willebrand factor (vWF) and P-selectin (CD62p) levels. MethodsA total of 84 ACS patients who were treated in our hospital from February 2018 to February 2020 were selected, and they were divided into two groups by the random number table method, with 42 cases in each group. Patients in the control group were treated with PCI and conventional treatment, based on which patients in the experimental group were additionally treated with Ningxin Huoxue Qutan decoction as the adjuvant treatment, for a two-month treatment course. The clinical efficacy, the serum levels of vWF, CD62p and glycoprotein (GP) Ⅱb/Ⅲa receptor complex before and after treatment were compared between the two groups. ResultsThe total effective rate of treatment in the experimental group (90.48%) was significantly higher than that in the control group (71.43%), and the difference was statistically significant (P＜0.05). There were no statistically significant differences in the levels of serum vWF, P-selectin CD62p, GP Ⅱb/Ⅲa receptor complex between the two groups before treatment (P＞0.05). The serum CD62p, vWF, and GPⅡb/Ⅲa receptor complex levels of the experimental group were significantly lower than those of the control group after 2 months of treatment, and the differences were statistically significant (P＜0.05). There were no obvious abnormalities in liver and kidney function, urine routine and blood routine of the two groups, and no obvious adverse reactions occurred during the treatment. ConclusionThe adjuvant treatment of Ningxin Huoxue Qutan decoction can effectively improve the angina pectoris of ACS patients after PCI, improve the function of vascular endothelial cells and platelet activity in patients. And thus it is highly safe for treatment.

备注/Memo

备注/Memo:

▲基金项目：河南省科技攻关计划项目（201702333）

常用功能

更新日期/Last Update: 2021-01-11